Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 12/05/25
Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 11/27/25
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & OncologyPRNewsWire • 11/17/25
All You Need to Know About Rigel (RIGL) Rating Upgrade to Strong BuyZacks Investment Research • 11/06/25
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/04/25
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and ExpositionPRNewsWire • 11/03/25
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'CNBC • 10/30/25
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business UpdatePRNewsWire • 10/29/25
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?Zacks Investment Research • 10/15/25
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Rigel (RIGL)Zacks Investment Research • 10/14/25
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDSPRNewsWire • 10/08/25
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?Zacks Investment Research • 09/29/25
Rigel (RIGL) Loses 27.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 09/26/25
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?Zacks Investment Research • 09/25/25
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?Zacks Investment Research • 09/18/25